We then sought to restore the DMD reading frame in DMDΔE52 myotubes through exon skipping, a current treatment for certain DMD patients with specific mutations in DMD. For example, eteplirsen is an FDA-approved ASO designed to treat DMD patients with a disrupted reading frame that can be restored by the skipping of exon 51 (refs. 44,45), which allows the production of an internally deleted but partially functional dystrophin protein. This evidence concerns the gene DMD and Duchenne muscular dystrophy.